Frontage Laboratories Names New Head of Global CMC Services

Exton, P.A., (July 16, 2013) – Frontage Laboratories today announces the appointment of Dr. Cheryl Li as Senior Vice President, Global CMC Services. Frontage's CMC Services division offers an integrated service portfolio ranging from dosage form product development, contract manufacturing, pharmaceutical analysis, organic syntheses to CMC strategy consulting. Dr. Li's position is an initial step of Frontage's corporate strategic expansion in CMC infrastructure to meet growing development needs in novel drugs, generic products and biosimilars.

"Cheryl Li brings an impressive tenure of designing and leading successful growth and innovation strategies for organizations of different sizes across biopharmaceuticals, consumer healthcare and consumer product industries through deploying a balanced approach using strategic partnerships, licensing and acquisitions and internal innovation execution, "said Dr. Song Li, Chairman and CEO. "I'm confident that Frontage will significantly benefit from her broad technical knowledge, global industry network, and business experience driving strong collaborations as the company enters its next phase of growth."

Prior to joining Frontage, Dr. Cheryl Li held several management positions at Johnson and Johnson Consumer Group companies. Most recently, she was Director, Global Innovation Sourcing and Strategic Partnership, where she led growth initiatives involving product and process technologies for OTC, health and nutrition, skin, oral and personal care businesses. Previously, she was Director, Strategic Sourcing/External Technology & Supply, where she led design of sourcing strategies for emerging technologies and set-up of external supply chains for new and existing OTC products. Earlier, she was Director of Technical Operations at Mallinckrodt Baker/Covidien and led product development groups at Albany Molecular Research Inc. and Honeywell. 

"Frontage recognizes the need for speedy and creative solutions to enable its diverse client base to win the race for new and differentiated products," said Dr. Cheryl Li. "With an established presence in both mature and emerging markets, I am excited to build upon Frontage's existing reputation for technical expertise as well as speed and quality of delivery within its CMC services at this pivotal stage of Frontage's growth."

Dr. Cheryl Li received a doctor of philosophy degree in pharmaceutical sciences from the University of Connecticut. She earned a master's of science degree and a bachelor's of science degree in chemistry from Peking University in China.

About Frontage

Frontage Laboratories helps biopharmaceutical organizations advance early-phase research and development with full service offerings – including bioanalysis, preclinical and clinical studies, analytical testing and product development support– that spans discovery stages through Phase II clinical trials. Frontage also provides turnkey product development, bioequivalence and analytical services to generic pharmaceutical companies to support ANDA submissions.

With a 12-year history of bioanalytical, clinical research and CMC operations, five state-of-the art research facilities and more than 300 professionals in the US and China, Frontage has enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development and commercial launch in global markets. For more information, visit


Katherine Cloninger

Director, Marketing

[email protected]